Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week randomized placebo-controlled trial of anacetrapib added to statin therapy in hypercholesterolemia or low HDL-C
2012-003110-14Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and Hypo-HDL cholesterolemia (HALP) comparing anacetrapib + statin with placebo + statin (2 arms). Primary endpoint: LDL-C (BQ method). Started Oct 2012; status: completed.
02
Drugs
anacetrapib
03
Conditions
hypercholesterolemiaHypo-HDL cholesterolemia (HALP)
Beyond the preview
Go deeper on 2012-003110-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003110-14.